JAMA Network Home
Sign In
Special Communication

RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season

JAMA 10.1001/jama.2026.17871

September 02, 2026 at 10:00 AM EDT

Read the full article

RSV immunizations were associated with reduced risk of severe RSV and RSV-related hospitalizations; evidence among older adults suggests that RSV VE may be lower in subsequent seasons. Reported adverse events of special interest (including GBS and preterm birth) were consistent with prior reviews. The results of this updated review are both consistent with previously reported evidence and provide new insight into several aspects of RSV immunizations.

MEDIA ADVISORY: 2026-27 Respiratory Virus Immunization Recommendations

Recommendations are informed by JAMA evidence reviews on influenza, COVID-19, and RSV.

An accompanying Perspective describes the background of the Vaccine Integrity Project, outlines the process for the 2026-2027 evidence review, and summarizes key findings regarding vaccine effectiveness and safety.

EMBARGOED PRESS BRIEFING: Tuesday, September 1

The Vaccine Integrity Project, the American Medical Association (AMA), and leading medical specialty societies will participate in an embargoed press briefing to outline the latest data on influenza, COVID-19 and RSV immunization, and to provide evidence-based recommendations for the upcoming 2026-27 respiratory virus season.

Recommendations are based on evidence reviews on influenza, COVID-19, and RSV, along with an accompanying Perspective, publishing at 10 A.M. EDT Wednesday, September 2, in JAMA.

WHAT: Embargoed press briefing for 2026-2027 respiratory virus scientific evidence and immunization recommendations

WHEN: 1 P.M. EDT Tuesday, September 1

WHERE: The briefing will be via Zoom. Register online.

WHO:

  • Nicole Basta, PhD, MPhil, Vaccine Integrity Project Evidence Review Co-Lead

  • Christina Davidson, MD, American College of Obstetricians and Gynecologists (ACOG) Chief Medical Officer

  • Sandra Adamson Fryhofer, MD, AMA President-elect

  • Bruce Gelin, PhD, Vaccine Integrity Project Board of Advisors

  • Ronald G. Nahass, MD, MHCM, FIDSA, President of Infectious Diseases Society of America (IDSA)

  • Sarah C. Nosal, MD, FAAFP, American Academy of Family Physicians (AAFP) President

  • Andrew D. Racine, MD, PhD, American Academy of Pediatrics (AAP) President.

Corresponding Author: Nicole E. Basta, PhD, MPhil, Division of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, 2001 McGill College Ave, Ste 1200, Montréal, QC H3A 1G1, Canada (nicole.basta@mcgill.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.17871?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090226

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks